Phillip Frost Purchases $891,000 Worth of OPKO Health Shares

Phillip Frost, Chairman & CEO of OPKO Health, has purchased a handful of shares worth $891k at an average price of $1.32, increasing their holding size by 0.3%. This is the largest insider purchase in the last year. Frost has bought 3.44m shares over the year at an average price of $1.51. Insider ownership in OPKO Health is 44%, worth $437m, indicating that management incentives are well aligned with other shareholders.

OPKO Health, Inc., a biotechnology company, recently saw its Chairman and Chief Executive Officer, Phillip Frost, purchase a significant number of shares. On July 2, 2025, Frost bought a total of 3.44 million shares worth $891,000 at an average price of $1.32, increasing his holding size by 0.3%. This is the largest insider purchase by Frost in the past year, indicating a strong belief in the company's future prospects.

Frost's total insider ownership in OPKO Health stands at 44%, valued at $437 million, which aligns with his compensation and long-term incentives. This substantial insider ownership suggests that management's interests are well-aligned with those of other shareholders, fostering a sense of confidence in the company's leadership.

In addition to this insider purchase, OPKO Health reported its second-quarter 2025 financial results on July 31, 2025. The company experienced a GAAP net loss of $148.4 million for the quarter, compared to $10.3 million in the same period last year. The loss was attributed to slower-than-anticipated adoption of long-acting growth hormone therapy (INGENLA) and lower-than-expected profit contributions from its Pfizer partnership. The diagnostics segment reported an operating loss of $18.2 million, down from $26.6 million in Q2 2024, reflecting cost reductions and restructuring benefits.

The pharmaceutical segment incurred a loss of $28.7 million, up from $24.8 million in Q2 2024, primarily due to increased R&D spending. The company's total consolidated operating loss improved to $60 million, down from $61.7 million in Q2 2024, driven by lower expenses in the diagnostics segment.

OPKO Health expects total revenue of $640 million to $660 million for the full year 2025, with services revenue projected at $400 million to $425 million. The company anticipates total costs and expenses to be between $835 million and $865 million for the year, excluding one-time restructuring costs. The company is also expecting a gain on the oncology transaction closure, which is anticipated to be $100 million.

The company's R&D spending is expected to be $120 million to $130 million for 2025, with BARDA funding offsetting $30 million to $35 million of this cost. OPKO Health has also completed a major convertible debt exchange, which reduced its debt by over $159 million but incurred a $92 million expense.

In summary, while OPKO Health reported a significant net loss for Q2 2025, the company's strategic initiatives, including the sale of BioReference oncology assets and increased R&D spending, are aimed at driving future growth and profitability. Chairman Frost's recent insider purchase further underscores his confidence in the company's prospects.

References:
[1] https://www.fool.com/earnings/call-transcripts/2025/08/07/opko-health-opk-q2-2025-earnings-call-transcript/